Cardiovascular risks associated with protease inhibitors for the treatment of HIV

Keyphrases

• Area Cover 25%
• Arterial Elasticity 25%
• Arterial Stiffness 25%
• Atazanavir 75%
• Atherosclerotic Markers 25%
• Cardiovascular Disease 25%
• Cardiovascular Events 25%
• Cardiovascular Risk 100%
• Carotid Intima-media Thickness (cIMT) 25%
• Conference Abstracts 25%
• CVD Risk 25%
• Darunavir 100%
• Drug Discontinuation 25%
• Dyslipidemia 50%
• Expert Opinion 25%
• First-generation Protease Inhibitors 25%
• HIV Treatment 25%
• Lipid Effects 25%
• Protease Inhibitors 100%
• PubMed 25%
• Randomized Trial 25%
• Salvage Therapy 25%
• Search Terms 25%
• Tolerability 25%
• Two-drug Regimen 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Atazanavir 60%
• Cardiovascular Disease 40%
• Cardiovascular Risk 100%
• Darunavir 80%
• Dyslipidemia 40%
• HIV 100%
• Observational Study 20%
• Proteinase Inhibitor 100%
• Tolerability 20%